Mylan Wins Its Amlodipine Case With Pfizer

U.S. Court of Appeals for the Federal Circuit Reverses District
Court Judgment

PITTSBURGH, June 05, 2007 /PRNewswire-FirstCall/ -- Mylan
Laboratories Inc. today announced that the U.S. Court of Appeals
for the Federal Circuit today granted its motion for a reversal of
the district court judgment in its patent infringement litigation
with Pfizer concerning amlodipine besylate. On February 22, 2007,
the district court for the Western District of Pennsylvania had
ruled in favor of Pfizer and Mylan immediately appealed and has
continued to fully expect a reversal of the decision. Mylan was
able to launch its amlodipine products following a March 22, 2007
decision by the U.S. Court of Appeals for the Federal Circuit that
claims 1-3 of the amlodipine '303 patent were invalid.

Robert J. Coury, Mylan's Vice Chairman and Chief Executive
Officer commented: "We are pleased to have prevailed in our
amlodipine besylate litigation and the judicial system ultimately
confirmed the position that we were the first to assert and have
consistently maintained concerning this product for over four
years. We are further pleased that our first to market generic
amlodipine products have saved patients, corporations, the
government and taxpayers hundreds of millions of dollars in
healthcare costs."

Amlodipine Besylate Tablets are the generic version of Pfizer's
Norvasc(R) Tablets, which had U.S. sales of approximately $2.7
billion for the 12-month period ending Dec. 31, 2006, according to
IMS Health.

Mylan Laboratories Inc. is a leading pharmaceutical company with
three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan
Technologies Inc. and UDL Laboratories Inc., and a controlling
interest in Matrix Laboratories Limited, India. Mylan develops,
licenses, manufactures, markets and distributes an extensive line
of generic and proprietary products.

This press release includes statements that constitute
"forward-looking statements," including with regard to the launch
of Amlodipine Besylate Tablets. These statements are made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Because such statements inherently involve
risks and uncertainties, actual future results may differ
materially from those expressed or implied by such forward- looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to: the use of legal,
regulatory and legislative strategies by competitors or other third
parties to delay or prevent product introductions; risks inherent
in legal proceedings; and the other risks detailed in the Company's
periodic filings with the Securities and Exchange Commission. The
Company undertakes no obligation to update these statements for
revisions or changes after the date of this release.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.